Welcome!

News Feed Item

Jury to Roche: You Failed to Properly Warn Physicians of the Risk of Ulcerative Colitis with Acne Drug Accutane; Roche Ordered to Pay $1.59 Million to Former Accutane User, according to Seeger Weiss LLP

ATLANTIC CITY, N.J., March 11, 2014 /PRNewswire/ -- A jury in New Jersey returned a $1.59 million verdict to a former Accutane user against N.J.-based pharmaceutical companies Hoffmann La-Roche Inc. and Roche Laboratories.  The plaintiff, Kamie Kendall Rees, was prescribed several courses of Accutane for treatment of her acne in the 1990s, starting at the age 12.  Shortly thereafter, Ms. Kendall Rees developed ulcerative colitis—a permanent, debilitating disease.  Unable to manage her disease, Ms. Kendall Rees was later forced to have her colon removed.  The trial was a re-trial of a 2008 verdict challenged by Roche to the New Jersey Supreme Court.

The trial team was led by Michael Hook of Hook Bolton (Pensacola, Florida) and David Buchanan of Seeger Weiss LLP (New Jersey/New York).  Further representing Ms. Kendall Rees were Mary Jane Bass and Jack Lurton of Beggs & Lane LLP, and Bill Cash and Troy Rafferty of Levin Papantonio.

In response to the verdict, Mr. Hook stated: "We're extremely pleased for Kamie.  She has suffered greatly at the hands of Roche's drug, and the jury's verdict provides a measure of justice for her."  Buchanan added, "The evidence revealed that Roche withheld its knowledge and conclusions about the risk of ulcerative colitis from doctors prescribing the drug, and thus patients, like Ms. Kendall Rees, and their parents who permitted its use, were completely unaware of the risks of this debilitating disease."  

The trial was the seventh New Jersey trial concerning Accutane to reach a verdict.  In the prior six trials on behalf of twelve former Accutane users, those juries also found that Roche had failed to provide an adequate warning of the risks of inflammatory bowel disease with Accutane.  There are currently more than 7,000 cases pending in New Jersey and elsewhere on behalf of former Accutane users who developed serious gastrointestinal diseases after using the drug.

Mr. Hook commented that, "though the jury's verdict only formally applies to Kamie, it's an extremely positive result for plaintiffs in the remaining approximately 7,000 inflammatory bowel disease cases pending in New Jersey and elsewhere."  Ms. Kendall was prescribed Accutane in the late 1990s—from 1997 through 1998.  Mr. Hook further noted that, "From 1984 through 1998, Roche failed to strengthen the warning in the Accutane label in the face of mounting internal and external evidence of the severe risk of ulcerative colitis with the use of its drug.  The jury's finding that the label was inadequate through as late as 1998 will have broader impact in other cases going forward."

Similarly, Mr. Buchanan emphasized the broader significance of the jury's rejection of Roche's defense that Accutane does not cause ulcerative colitis, adding:  "Like the juries in each of the prior trials that were asked the question, the jury here concluded that Accutane is a cause of inflammatory bowel disease, in this case, ulcerative colitis."  Referred to in legal circles as "general causation," Mr. Buchanan noted that, "At this point, Accutane's role as a cause of ulcerative colitis is a settled issue.  Roche's continued denials in the face of seven juries in New Jersey, and one in Florida, stating otherwise is a continuing insult to the many who have already suffered so much due to this drug." 

Hook Bolton (www.hookbolton.com) is a Pensacola, Florida based personal-injury law firm.  Seeger Weiss LLP (www.seegerweiss.com) is a New York/New Jersey trial law firm focusing on complex and catastrophic injury litigation.  For more information, please contact Michael Hook (850-433-0809) or David Buchanan (212-584-0700).

 

SOURCE Seeger Weiss LLP

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
Creating replica copies to tolerate a certain number of failures is easy, but very expensive at cloud-scale. Conventional RAID has lower overhead, but it is limited in the number of failures it can tolerate. And the management is like herding cats (overseeing capacity, rebuilds, migrations, and degraded performance). In his general session at 18th Cloud Expo, Scott Cleland, Senior Director of Product Marketing for the HGST Cloud Infrastructure Business Unit, discussed how a new approach is neces...
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
The Founder of NostaLab and a member of the Google Health Advisory Board, John is a unique combination of strategic thinker, marketer and entrepreneur. His career was built on the "science of advertising" combining strategy, creativity and marketing for industry-leading results. Combined with his ability to communicate complicated scientific concepts in a way that consumers and scientists alike can appreciate, John is a sought-after speaker for conferences on the forefront of healthcare science,...
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Software-defined storage is a big problem in this industry because so many people have different definitions as they see fit to use it," stated Peter McCallum, VP of Datacenter Solutions at FalconStor Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
"Our strategy is to focus on the hyperscale providers - AWS, Azure, and Google. Over the last year we saw that a lot of developers need to learn how to do their job in the cloud and we see this DevOps movement that we are catering to with our content," stated Alessandro Fasan, Head of Global Sales at Cloud Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
"We're focused on how to get some of the attributes that you would expect from an Amazon, Azure, Google, and doing that on-prem. We believe today that you can actually get those types of things done with certain architectures available in the market today," explained Steve Conner, VP of Sales at Cloudistics, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. Commvault can ensure protection, access and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his general session at 18th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Part...